乙型肝炎病毒相关性肾炎诊治进展  

Diagnosis and Treatment Progress of Hepatitis B virus-associated Glomerulonephritis

作　　者：庞浩文 PANG Hao-Wen(Emergency Department,Affiliated Hospital Of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属医院急诊科

出　　处：《中国药物经济学》2019年第11期126-128,共3页China Journal of Pharmaceutical Economics

摘　　要：乙型肝炎病毒相关性肾炎(HBV-GN)是我国较为多见疾病之一,其是在致病因素及乙型肝炎病毒(HBV)感染协同作用下产生的多级、繁杂的病变过程,易发生多器官受损,好发于青壮年及儿童。目前临床治疗药物主要包括抗病毒药物、糖皮质激素、免疫抑制剂、中药治疗等。但对于该疾病最佳的临床方案至今尚未明确,治疗时应结合患者临床表现、肾脏病理改变、肝功能及HBV-DNA指标制订合理方案,在短时间内最大程度地减少HBV复制。Hepatitis B virus-associated glomerulonephritis(HBV-GN) is one of the most common diseases in China. It is a multi-stage and complicated disease process produced by the synergistic effect of pathogenic factors and hepatitis B virus(HBV) infection. It is prone to multiple organ damage, and is predominant in young adults and children. At present, clinical therapeutic drugs mainly include antiviral drugs, glucocorticoids, immunosuppressive agents, Chinese medicine treatment etc.. However, the best clinical plan for the disease has not been clear yet. The reasonable plan should be formulated in combination with clinical manifestations, pathological changes of kidney, liver function and HBV-DNA indicators to minimize HBV replication in a short period of time.

关 键 词：乙型肝炎病毒相关性肾炎 糖皮质激素 联合用药 中医治疗 

分 类 号：R692.3[医药卫生—泌尿科学] R983[医药卫生—外科学]